望月 眞弓 (モチヅキ マユミ)

Mochizuki, Mayumi

写真a

所属(所属キャンパス)

薬学部 薬学科 (芝共立)

職名

特任教授(有期)

 
 

著書 【 表示 / 非表示

  • 現代用語の基礎知識2019

    望月 眞弓, 自由国民社, 2018年11月

    担当範囲: 薬と社会

  • くすり創りの歴史

    内藤記念くすり博物館, 2018年08月

    担当範囲: 監修

  • 現代用語の基礎知識2018

    望月 眞弓, 自由国民社, 2017年11月

    担当範囲: 薬と社会

  • スタンダード薬学シリーズⅡ6 医療薬学Ⅶ 製剤化のサイエンス

    東京化学同人, 2017年10月

    担当範囲: 編集責任

  • スタンダード薬学シリーズⅡ6 医療薬学Ⅴ 薬物治療に役立つ情報

    東京化学同人, 2017年10月

    担当範囲: 編集責任

全件表示 >>

論文 【 表示 / 非表示

  • Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics


    Matsuoka K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Nagauma M., Kanai T., Mochizuki M., Hashiguchi M.

    International journal of clinical pharmacology and therapeutics (International journal of clinical pharmacology and therapeutics)  58 ( 2 ) 89 - 102 2020年02月

    ISSN  09461965

     概要を見る

    OBJECTIVE: Crohn's disease (CD) is a chronic inflammatory gastrointestinal disease with repeated cycles of exacerbation and remission. Infliximab (IFX), a chimeric anti-TNF-α monoclonal antibody, has been widely used for the treatment of CD. However, no study in Japanese CD patients receiving continuous IFX for more than 1 year has been reported. To avoid therapeutic failure during long-term administration in Japanese CD patients, we evaluated the variable factors of IFX pharmacokinetics and the optimal trough IFX concentration at 8 weeks after administration. MATERIALS AND METHODS: Population pharmacokinetic (PPK) analysis was performed using the nonlinear mixed-effect model based on the IFX serum concentration in 832 samples from 121 patients. A one-compartment model was used to examine interindividual variability in the systemic clearance (CL) of intravenously administered IFX. RESULTS: PPK estimates (estimated value, RSE%) were total clearance (CL: 0.018 L/h, 9.1) and volumes of distribution (Vd: 7.35 L, 12.0). Interindividual variability for CL and Vd of 0.11 and 0.16, respectively, was found. Body weight, antibody to IFX (ATI), and albumin level were factors affecting the IFX CL. IFX CL was greater in the ATI-positive than in the ATI-negative group. CL was also greater in nonremission patients. There was a significant association between the predicted serum IFX trough concentration at 8 weeks and therapeutic response with long-term continuous administration (p < 0.05), with a higher concentration at 8 weeks seen in the remission group. CONCLUSION: Using these variables including body weight, ATI, and albumin level, the IFX dose could be calculated for individual CD patients to achieve the optimal therapeutic range.

  • Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine

    Akiyama S., Matsuoka K., Fukuda K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Naganuma M., Motobayashi M., Suzuki K., Takenaka K., Fujii T., Saito E., Nagahori M., Ohtsuka K., Mochizuki M., Watanabe M., Hashiguchi M., Kanai T.

    Journal of Gastroenterology and Hepatology (Australia) (Journal of Gastroenterology and Hepatology (Australia))  34 ( 10 ) 1751 - 1757 2019年10月

    ISSN  08159319

     概要を見る

    © 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd Background and Aim: A missense variant of the nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) gene (R139C) predisposes Asian patients with inflammatory bowel disease (IBD) to thiopurine-induced leukopenia. This study evaluates the long-term effect of NUDT15 R139C heterozygosity on hematological parameters during thiopurine administration. Methods: We enrolled 83 Japanese IBD patients who were on anti-tumor necrosis factor-α agents and had used thiopurine. NUDT15 R139C was genotyped by polymerase chain reaction. We retrospectively reviewed patient clinical charts to collect data on white blood cell (WBC) count, mean corpuscular volume (MCV), hemoglobin, and platelet count during the 24 months following thiopurine initiation. Results: The included patients had either Crohn's disease (54; 65.1%) or ulcerative colitis (29; 34.9%). Genotyping of NUDT15 R139C identified 62 patients (74.7%) of genotype C/C and 21 (25.3%) of genotype C/T. The median dose of thiopurine was lower in the C/T group than in the C/C group after starting thiopurine. At 6 months, the mean WBC count of the C/T group became significantly lower than that of the C/C group (P = 0.008) and remained lower through the 24 months. The C/T group developed grade 2–4 leukopenia by 6 months, which persisted through 12–24 months. The mean MCV in the C/T group became higher than that of the C/C group after 3 months. Conclusions: NUDT15 R139C heterozygosity affected the WBC count and MCV for 24 months after thiopurine administration. Our results indicate that careful monitoring of leukopenia and dose adjustment are necessary throughout treatment in IBD patients heterozygous for the NUDT15 R139C.

  • Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: A validation study at a single center

    Ando T., Ooba N., Mochizuki M., Koide D., Kimura K., Lee S., Setoguchi S., Kubota K.

    BMC Health Services Research (BMC Health Services Research)  18 ( 1 )  2018年11月

     概要を見る

    © 2018 The Author(s). Background: In Japan, several large healthcare databases have become available for research since the early 2000's. However, validation studies to examine the accuracy of these databases remain scarce. We conducted a validation study in order to estimate the positive predictive value (PPV) of local or ICD-10 codes for acute myocardial infarction (AMI) in Japanese claims. In particular, we examined whether the PPV differs between claims in the Diagnosis Procedure Combination case mix scheme (DPC claims) and in non-DPC claims. Methods: We selected a random sample of 200 patients from all patients hospitalized at a large tertiary-care university hospital between January 1, 2009 and December 31, 2011 who had an inpatient claim assigned a local or ICD-10 code for AMI. We used a standardized data abstraction form to collect the relevant information from an electronic medical records system. Abstracted information was then categorized by a single cardiologist as being either definite or not having AMI. Results: In a random sample of 200 patients, the average age was 67.7 years and the proportion of males was 78.0%. The PPV of the local or ICD-10 code for AMI was 82.5% in this sample of 200 patients. Further, of 178 patients who had an ICD-10 code for AMI based on any of the 7 types of condition codes in the DPC claims, the PPV was 89.3%, whereas of the 161 patients who had an ICD-10 code for AMI based on any of 3 major types of condition codes in the DPC claims, the PPV was 93.8%. Conclusion: The PPV of the local or ICD-10 code for AMI was high for inpatient claims in Japan. The PPV was even higher for the ICD-10 code for AMI for those patients who received AMI care through the DPC case mix scheme. The current study was conducted in a single center, suggesting that a multi-center study involving different types of hospitals is needed in the future. The accuracy of condition codes for DPC claims in Japan may also be worth examining for conditions other than AMI such as stroke.

  • Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease

    Matsuoka K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Naganuma M., Kanai T., Mochizuki M., Hashiguchi M.

    PLoS ONE (PLoS ONE)  13 ( 10 )  2018年10月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  1932-6203

     概要を見る

    © 2018 Hsieh et al. Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and remission in patients with moderate to severe inflammatory bowel disease (IBD), the use of anti-TNF therapies has fundamentally changed the approach to treatment for patients with IBD. Infliximab (IFX) is a TNF-α inhibitor approved for the induction and remission of Crohn's disease (CD). However, even among patients who initially demonstrate a clinical response to IFX therapy, secondary loss of response occurs, although the reason remains unknown. We therefore investigated predictive factors associated with the response to IFX in long-term maintenance treatment in Japanese CD patients. Eight types of single-nucleotide polymorphisms (SNPs) were investigated using the real-time PCR method, and patient characteristics were collected from the electronic medical records. The Crohn's Disease Activity Index criteria were used as the response to IFX therapy. The observation period was 1 year after IFX had been administered for more than 1 year. Associations between the IFX response and patient characteristics were evaluated using the multivariate logistic regression model. We studied 121 unrelated adult Japanese with CD treated for more than 1 year with IFX as outpatients at Keio University Hospital from November 1, 2014 to November 30, 2015. Among them, 71 were classified as in remisson. In multivariate analysis, patients with the TNF-α 857C>T C/C genotype, shorter disease duration, without double dosing, and combination treatment with an immunomodulator had higher remisson rates than those with the C/T or T/T genotype, longer disease duration, with double dosing, and no combination treatment with an immunomodulator. The response to IFX in Japanese CD patients may therefore be predicted by these 4 characteristics in actual clinical practice.

  • Factors predicting the therapeutic response to methotrexate in Japanese patients with rheumatoid arthritis: A hospital-based cohort study

    Hakamata J., Kaneko Y., Shimizu M., Yamaoka K., Maruyama J., Takeuchi T., Mochizuki M., Hashiguchi M.

    Biological and Pharmaceutical Bulletin (Biological and Pharmaceutical Bulletin)  41 ( 9 ) 1414 - 1422 2018年09月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  0918-6158

     概要を見る

    © 2018 The Pharmaceutical Society of Japan. Methotrexate (MTX) is used widely as a first-line drug for the treatment of rheumatoid arthritis (RA) worldwide. There are large interindividual differences in the therapeutic response to MTX, but it is not known which factors influence them. We therefore investigated predictive factors associated with the therapeutic response to MTX in a hospital-based cohort study. Japanese adult RA outpatients prescribed MTX were enrolled and their characteristics were collected from the electronic medical records. The European League Against Rheumatism (EULAR) response criteria were used as the response to MTX therapy. The observation period was 1 year after beginning MTX administration. Sixteen types of single-nucleotide polymorphisms were investigated using the real-time PCR method. Associations between the MTX response and patient characteristics were evaluated using the multivariate logistic regression model. Among 70 Japanese adult RA outpatients, 52 were classified as MTX responders. In multivariate analysis, patients with the solute carrier family 19 member 1 (SLC19A1) 80G>A A/A genotype had a better response than those with the A/G or G/G genotype, and patients with the C allele of γ-glutamyl hydrolase (GGH) 16T>C had a better response than those with the T/T genotype.This study showed that the therapeutic response to MTX in Japanese RA patients was associated with the genetic polymorphisms of SLC19A1 80G>A and GGH 16T>C in actual clinical practice.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

総説・解説等 【 表示 / 非表示

  • The report: Promotion of social contributions of research on clinical pharmacy and pharmaceutical sciences

    Mochizuki M.

    Yakugaku Zasshi (Yakugaku Zasshi)  139 ( 3 ) 393 - 394 2019年

    ISSN  00316903

     概要を見る

    © 2019 The Pharmaceutical Society of Japan. The Science Council of Japan issued ``The report: Promotion of Social Contributions of Research on Clinical Pharmacy and Pharmaceutical Sciences'' on September 29, 2017. This report was prepared based on the analysis of current situation of the four-year doctoral course in the graduate school of pharmacy and the contents of the symposium of 137th annual meeting of the Pharmaceutical Society of Japan (PSJ), ``Pharmaceutical Sciences in the Future: The Bridge Linking between Basic and Clinical Research''. The goal of the 4-year doctoral program is to nurture the phar-macist-scientist who has both researcher mind and professionalism as a clinical pharmacist. Research on clinical pharmacy and pharmaceutical sciences is a core research area of the 4-year doctoral course, therefore its promotion is an important issue for the faculty of pharmacy. ``Research on clinical pharmacy and pharmaceutical sciences'' has to be based on various subjects and needs of the clinical site and be conducted not only at the clinical setting but also in universities, industries, research institutions and so on. Finally, the results have to be fed back to medical care and contribute to society. In this symposium, several representatives from various academic societies and one research institution which have important functions for academic interchanges, will give presentations on issues and initiatives for promoting research on clinical pharmacy and pharmaceutical sciences.

  • Sustainableな薬学図書館であるために

    望月 眞弓

    薬学図書館 63 ( 4 ) 205 - 210 2018年10月

    総説・解説(学術雑誌), 単著

  • 【老年医学(上)-基礎・臨床研究の最新動向-】 高齢患者へのアプローチ 高齢者の薬物治療 Potentially Inappropriate Medicine(PIM)

    望月 眞弓, 青森 達

    日本臨床 (日本臨床)  76 ( 増刊5 ) 347 - 353 2018年06月

    総説・解説(商業誌、新聞、ウェブメディア), 共著

  • 【私の処方2018】 添付文書の読み方

    望月 眞弓

    小児科臨床 (日本小児医事出版社)  71 ( 5 ) 611 - 620 2018年05月

    総説・解説(商業誌、新聞、ウェブメディア), 単著

  • 薬剤師inプライマリ・ケア 大学病院における薬剤師の活躍

    山口 雅也, 望月 眞弓

    プライマリ・ケア 3 ( 1 ) 57 - 59 2018年03月

    総説・解説(学術雑誌), 共著

全件表示 >>

研究発表 【 表示 / 非表示

  • 医薬品安全性情報の自発報告の位置づけ 患者からの副作用報告システムの構築の経験から 経緯、現状と課題

    橋口正行、望月眞弓

    日本薬剤疫学会学術総会第24回 Page34-35(2018.10) (仙台) , 2018年10月, シンポジウム・ワークショップ パネル(指名), 日本薬剤疫学会

  • 医療用医薬品添付文書の古くて新しい話

    望月 眞弓

    第38回日本臨床薬理学会 (京都) , 2018年07月, 公開講演,セミナー,チュートリアル,講習,講義等, 日本臨床薬理学会

  • 日本病院薬剤師会策定「医薬品情報業務の進め方2018」と私のDI業務 日本病院薬剤師会策定「医薬品情報業務の進め方2018」の概要

    望月 眞弓

    第21回日本医薬品情報学会総会・学術大会 (鈴鹿) , 2018年06月, シンポジウム・ワークショップ パネル(公募), 日本医薬品情報学会

  • プラセボ効果の個体間変動要因の検討のためのスタディプロトコール

    横山 由佳, 神成 はるか, 井澤 美苗, 早川 智久, 青森 達, 望月 眞弓

    第21回日本医薬品情報学会総会・学術大会 (鈴鹿) , 2018年06月, ポスター(一般), 日本医薬品情報学会

  • 製薬会社によるデジタル化された医薬品情報の提供・利活用に関する調査

    中田 英夫, 石川 春樹, 木村 元範, 我妻 秀和, 村松 博, 望月 眞弓

    第21回日本医薬品情報学会総会・学術大会 (鈴鹿) , 2018年06月, ポスター(一般), 日本医薬品情報学会

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • 工学的発想と臨床心理学的発想に基づく一般用医薬品添付文書の開発

    2015年04月
    -
    2018年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 望月 眞弓, 基盤研究(C), 補助金,  代表

受賞 【 表示 / 非表示

  • 福澤賞

    望月眞弓, 2018年11月, 慶應義塾, 医薬品情報学に関する先駆的な教育・研究と学術への貢献

    受賞区分: 塾内表彰等,  受賞国: 日本

  • 日本医療薬学会功績賞

    2016年09月, 日本医療薬学会

    受賞区分: 国内学会・会議・シンポジウム等の賞,  受賞国: 日本

  • 永井記念国際女性科学者賞

    2016年06月, 日本薬剤学会

    受賞区分: 国内外の国際的学術賞

  • 日本医薬品情報学会論文賞

    橋口正行、金子梨沙、保坂藍、植田恵子、小寺典子、中村眞弓、榊原幹夫、黒川達夫、望月眞弓., 2013年08月, 日本医薬品情報学会, 一般用医薬品の添付文書理解度調査法の開発、ー理解度への影響因子の検討ー.

  • 私立薬科大学協会教育賞

    望月眞弓, 2012年03月, 私立薬科大学協会

    受賞区分: その他の賞,  受賞国: 日本

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • 課題研究(病院薬学)

    2019年度

  • 演習(病院薬学)

    2019年度

  • 医療系薬学特論Ⅰ

    2019年度